The cancer center program of the NCI is a success that is admired not only within the NIH but worldwide. This is due, in large part, to the cancer center review process that has evolved and strengthened over the years.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
